Firstline therapy for fit patients eligible for diseasedirected therapy is Dara+CyBorD (daratumumab, cyclophosphamide, bortezomib, and dexamethasone) as initial induction therapy [22, 79]
"CEO Mike Doustdar and EVP, US Operations, Dave Moore were the only two Novo Nordisk representatives in the Oval Office
Cardiovascular disease is the leading cause of death in both men and women in the US and globally
The hypothesis is that by avoiding -arrestin recruitment, a GLP-1 agonist like CT-996 could lead to less receptor desensitization, decreased internalization, and improved long-term efficacy and tolerability
It releases inflammatory compounds, disrupts hormone signaling, and directly contributes to arterial damage
Novel Trajectories Towards Possible Effects of Semaglutide for Amelioration of Reserpine-induced Fibromyalgia in Rats